

Title (en)

METHODS FOR PROPHYLACTICALLY PREVENTING, SLOWING THE PROGRESSION OF, OR TREATING CEREBRAL AMYLOID ANGIOPATHY, ALZHEIMER'S DISEASE AND/OR ACUTE STROKE

Title (de)

VERFAHREN ZUR PROPHYLAXE, VERLANGSAMUNG DES FORTSCHREITENS ODER BEHANDLUNG VON ZEREBRALER AMYLOIDANGIOPATHIE, MORBUS ALZHEIMER UND / ODER AKUTEM SCHLAGANFALL

Title (fr)

PROCÉDÉS DE PRÉVENTION PROPHYLACTIQUE, DE RALENTISSEMENT DE L'ÉVOLUTION OU DE TRAITEMENT DE L'ANGIOPATHIE AMYLOÏDE CÉRÉBRALE, DE LA MALADIE D'ALZHEIMER ET/OU D'UN ACCIDENT VASCULAIRE CÉRÉBRAL AIGU

Publication

EP 3790573 A4 20220511 (EN)

Application

EP 19799475 A 20190510

Priority

- US 201862670615 P 20180511
- US 201862700804 P 20180719
- US 2019031832 W 20190510

Abstract (en)

[origin: WO2019217897A1] The present specification is directed to systems, apparatus and methods for prophylactically preventing, or for treating the onset and/or progression of Cerebral Amyloid Angiopathy (CAA), acute stroke conditions, or Alzheimer's disease. The progression of, stabilizing, or improving symptoms related to these conditions are treated by monitoring a pathophysiological change indicative of the conditions in a patient, based on the monitoring, determining if amyloid plaque is present in a perivascular space of the patient, optionally determining an extent of amyloid plaque in the perivascular space, and based on the presence of amyloid plaque in the perivascular space of the patient, determining a treatment protocol for the patient. The treatment protocol includes administering to the patient a high density lipoprotein composition derived from mixing a blood fraction with a lipid removing agent.

IPC 8 full level

A61K 38/17 (2006.01); **A61K 35/16** (2015.01); **A61P 25/28** (2006.01); **G01N 33/68** (2006.01)

CPC (source: EP)

A61K 35/16 (2013.01); **A61P 25/28** (2017.12); **G01N 33/6896** (2013.01); **G01N 2333/4709** (2013.01); **G01N 2800/2821** (2013.01); **G01N 2800/52** (2013.01)

Citation (search report)

- [XP] WO 2018160868 A1 20180907 - HDL THERAPEUTICS INC [US] & EP 3589272 A1 20200108 - HDL THERAPEUTICS INC [US]
- [I] T. L. LEWIS ET AL: "Overexpression of Human Apolipoprotein A-I Preserves Cognitive Function and Attenuates Neuroinflammation and Cerebral Amyloid Angiopathy in a Mouse Model of Alzheimer Disease", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 47, 19 November 2010 (2010-11-19), pages 36958 - 36968, XP055191163, ISSN: 0021-9258, DOI: 10.1074/jbc.M110.127829
- See references of WO 2019217897A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2019217897 A1 20191114; AU 2019264938 A1 20201203; CA 3099999 A1 20191114; CN 112384237 A 20210219; EP 3790573 A1 20210317; EP 3790573 A4 20220511; JP 2021523182 A 20210902

DOCDB simple family (application)

US 2019031832 W 20190510; AU 2019264938 A 20190510; CA 3099999 A 20190510; CN 201980046386 A 20190510; EP 19799475 A 20190510; JP 2020563744 A 20190510